About
Technology
Issues
FAQ
Links
Official Page
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.